Dividend Win Wednesday: Semiconductors at 37% Off While Insiders Exit Energy at 11% Dips
Top 5 Pixie Picks
Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Dividend stocks.
Sign in →6. Biogen Inc. (BIIB)
Dividend yield: n/a | Payout ratio: 0% | 52w drawdown: -1.7%
Biogen trades at 24.4× earnings with a 5.9% FCF yield and sits 1.7% below its 52-week high, the smallest drawdown on the screen. The company has no dividend, meaning all free cash flow is available for buybacks or reinvestment, and shareholder yield data is absent because the payout ratio is zero.
Michael Parini filed insider buying September 3, and six-month insider activity shows 10 transactions with a net positive 3 shares and 100% buying. The stock hit a 52-week high in September, and the company reports October 28 with $2.03 EPS expected on $2.6 billion revenue.
Analyst consensus targets $219, 3.2% below the current price, and the 10-year normalized earnings yield is negative 1.2%, indicating that trailing profitability is elevated relative to the long-term average and may not be sustainable.
7. Nucor Corporation (NUE)
Dividend yield: 0.9% | Payout ratio: 29% | 52w drawdown: -15.2%
Nucor posted a negative 0.4% FCF yield in the trailing period, the only name on the screen with negative free cash flow, and trades at 23.6× earnings. Revenue grew 5.7% year-over-year, but the 12% gross margin is the lowest among the eight names, and the company sits 15% below its 52-week high.
Insider activity over six months is 100% selling, with negative 185,808 shares net. The company reports October 26 with $5.84 EPS expected on $10.8 billion revenue, and recent news includes a $15 billion Iowa steel mill partnership and Q3 guidance that missed consensus.
The setup depends on steel pricing and scrap availability; if HRC futures stay below $700 per ton and the Iowa mill delays capital deployment, the FCF yield remains negative and the dividend becomes vulnerable despite the 29% payout ratio.
8. Cigna Group (CI)
Dividend yield: 2.3% | Payout ratio: 28% | 52w drawdown: -12.8%
Cigna trades at 2.4× trailing earnings, the lowest P/E on the screen, with a 41.3% earnings yield and 11.5% FCF yield. The 10-year normalized earnings yield is 36.1%, indicating that trailing profitability is slightly above the long-term average but not at an unsustainable level.
Bruno Guicardi Neto filed three insider purchases in September: September 15, 23, and 29. The company hosted an Investor Day in September and introduced "Lead to One" to drive growth through complex care leadership, and the new CEO is focusing on specialty pharmacy within the Evernorth segment.
Net debt is 1.72× EBITDA, the second highest on the screen, and revenue growth of 11.7% year-over-year is strong but leaves the company exposed to pharmacy benefit manager margin compression if specialty drug pricing softens. The company reports November 5 with $7.49 EPS expected on $72.5 billion revenue.
What to Watch
• October 22: Newmont reports Q3 results; consensus expects $1.91 EPS on $6.3 billion revenue, and gold prices above $2,600 per ounce should drive margin expansion if production volumes hold.
• October 26–28: Nucor, Novartis, KLA, and Biogen all report earnings within a three-day window; the semiconductor and steel names will clarify whether recent revenue growth is sustainable or dependent on inventory restocking.
• November 5: ConocoPhillips, EOG, and Cigna report the same day; oil realizations and healthcare margin commentary will determine whether the FCF yields on the screen persist into Q4.
Go Deeper
The dividend screener looks for sustainable payout cover, strong FCF yields, and moderate drawdowns where income investors can compound through reinvestment.
Check out the full screener →
Pro-only analytics
Named tickers from this article open in the app with Pro or an active trial.
Sign in →Stock Pixie Pro
See the full dividend screen — every pick, every metric, every day.
The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.
Start your free trial →Or start with the free Market Brief Digest
Where the market stands before the open, in plain language, every trading day. No account needed.